https://www.zacks.com/stock/news/2243108/gsk-gsk-increases-yet-falls-behind-market-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2243108
Mar 19, 2024 - In the most recent trading session, GSK (GSK) closed at $42.32, indicating a +0.43% shift from the previous trading day.
zc:3031650112934949121
0
https://www.zacks.com/stock/news/2246352/gsk-gsk-stock-moves-0-09-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2246352
Mar 26, 2024 - GSK (GSK) closed at $42.79 in the latest trading session, marking a -0.09% move from the prior day.
zc:9206332608251634855
0
https://www.zacks.com/stock/news/2208092/gsk-to-buy-private-biotech-strengthen-respiratory-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208092
Jan 10, 2024 - GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
zc:-2407892645345568394
0
https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results?cid=CS-ZC-FT-analyst_blog|stock_roundup-2208960
Jan 11, 2024 - Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
zc:6787123533563202073
0
https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html
Jan 14, 2024 - The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.
0
cnbc:-607488078209698746
0
https://seekingalpha.com/news/4055337-gsk-to-sell-stake-in-spinoff-haleon-report?source=feed_sector_healthcare
Jan 16, 2024 - GSK (GSK) reportedly plans to sell a 3.2% stake in consumer healthcare products company Haleon (HLN), which it spun off in 2019. Read more here.
0
sa:4052322910772874025
0
https://seekingalpha.com/news/4057520-watch-gsk-amid-hearing-on-zantac-litigation?source=feed_sector_healthcare
Jan 23, 2024 - Investors should watch GSK amid a pre-trial hearing over litigation related to the heartburn medication Zantac, which could result in billions of...
0
sa:-2591871101345421979
0
https://www.zacks.com/stock/news/2215035/gsk-gsk-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2215035
Jan 24, 2024 - Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:-7735087620674684808
0
https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142
Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
zc:4097031735617591926
0
https://www.zacks.com/stock/news/2217328/gsk-gears-up-for-q4-earnings-will-it-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217328
Jan 29, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
zc:2736014490641346597
0